Products
FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia
Summary: The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and older with glycogen sto…
The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and older with glycogen storage disease type Ia (GSDIa)
Adults 21+. WINDBAR does not sell nicotine products on this site. Compliance statement.